摘要
目的观察慢性收缩性心力衰竭(CHF)患者血浆脑型钠尿肽(BN P)变化和丹参酮ⅡA磺酸钠注射液对其影响及疗效评定。方法将96例患者随机分为治疗组和对照组,2组均予西医常规治疗,治疗组加用丹参酮ⅡA磺酸钠注射液。2组分别于治疗前、治疗后14 d测定血浆BN P浓度,并观察2组治疗前后临床疗效、左室射血分数(LVEF)变化情况。结果治疗组和对照组治疗前BN P浓度接近,14 d后治疗组BN P水平低于对照组,其临床疗效、LVEF显著高于对照组。结论丹参酮ⅡA磺酸钠注射液治疗C H F疗效确切,可增加C H F患者LVEF,改善左室功能,提高运动耐量,降低血浆BN P水平,且安全性好。
Objective To observe the changes of Brain type natriuretic peptides（BNP） in patients with chronic systolic heart failure（CHF） and evaluate the efficacy of Sulfotanshinone Sodium Injection on it.Methods 96 patients were randomly divided into treatment group and control group.Both groups were given conventional Western medicine treatment,while the treatment group was given extra Sulfotanshinone Sodium Injection.The plasma BNP levels were detected before treatment and after treatment 14 days.Meanwhile the changes of clinical effects and left ventricular ejection fraction（LVEF） were observed.Results The plasma BNP levels pre-treatment were close to normal in the treatment group and the control group.While after 14 days treatment,the plasma BNP level decreased significantly in the treatment group.Its clinical efficacy and LVEF was significantly higher than control group.Conclusion Sulfotanshinone Sodium Injection for treatment of patients with CHF can increase LVEF and exercise tolerance,improve left ventricular function and decrease plasma BNP levels.And it is safe.
出处
《基层医学论坛》
2011年第28期877-879,共3页
The Medical Forum
作者简介
作者简介：孙海英，女，35岁，本科，毕业于潍坊医学院，主治医师。E—mail：xinxin200504@sina．com
